Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort

Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort

The CoronaVac vaccine is the most used anti-SARS-CoV-2 vaccine worldwide. Previous data indicate that this vaccine produces a lower immune response than RNA vaccines such as BNT162b2. End-stage renal disease (ESRD) patients have an increased rate of COVID-19 and a reduced immune response to vaccinat...

Full description

Bibliographic Details
Main Authors: Rene Clavero, Alfredo Parra-Lucares, Gabriel Méndez-Valdés, Eduardo Villa, Karin Bravo, Evelyn Mondaca, Josseline Aranda, Rose Brignardello, Cynthia Gajardo, Angelica Ordenes, Evelyn Colombo, Jessica Tapia, Andoni Etcheverry, José Zúñiga, Luis Toro
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Vaccines
Subjects:
renal dialysis
hemodialysis
COVID-19
SARS-CoV-2
immune response
antibody
Online Access:https://www.mdpi.com/2076-393X/10/9/1542

Internet

https://www.mdpi.com/2076-393X/10/9/1542

Similar Items